TransMedics Group, Inc. (NASDAQ:TMDX) Stake Reduced by Baillie Gifford & Co.

Baillie Gifford & Co. decreased its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 8.8% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 234,889 shares of the company’s stock after selling 22,577 shares during the period. Baillie Gifford & Co.’s holdings in TransMedics Group were worth $36,878,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. Vaughan Nelson Investment Management L.P. acquired a new stake in TransMedics Group during the second quarter valued at approximately $39,862,000. Driehaus Capital Management LLC increased its holdings in shares of TransMedics Group by 15.8% in the second quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock valued at $223,832,000 after buying an additional 202,867 shares in the last quarter. Principal Financial Group Inc. lifted its position in shares of TransMedics Group by 260.1% during the 3rd quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock valued at $31,759,000 after acquiring an additional 146,115 shares during the last quarter. Hood River Capital Management LLC bought a new stake in shares of TransMedics Group during the 2nd quarter worth $18,854,000. Finally, Canada Pension Plan Investment Board bought a new stake in shares of TransMedics Group during the 2nd quarter worth $16,086,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Stock Performance

Shares of NASDAQ TMDX opened at $91.41 on Wednesday. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. TransMedics Group, Inc. has a one year low of $56.83 and a one year high of $177.37. The business’s 50-day moving average price is $130.45 and its two-hundred day moving average price is $139.89. The company has a market capitalization of $3.07 billion, a P/E ratio of 97.25 and a beta of 2.08.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.17). The firm had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company’s quarterly revenue was up 63.7% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.12) EPS. Analysts anticipate that TransMedics Group, Inc. will post 1.07 earnings per share for the current fiscal year.

Insider Activity at TransMedics Group

In other TransMedics Group news, insider Nicholas Corcoran sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total transaction of $1,760,200.00. Following the transaction, the insider now directly owns 21,105 shares in the company, valued at $3,714,902.10. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Edward M. Basile sold 6,750 shares of TransMedics Group stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the transaction, the director now owns 732 shares of the company’s stock, valued at $61,158.60. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Nicholas Corcoran sold 10,000 shares of the company’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total transaction of $1,760,200.00. Following the sale, the insider now directly owns 21,105 shares of the company’s stock, valued at approximately $3,714,902.10. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 36,958 shares of company stock valued at $5,230,528. Insiders own 7.00% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on TMDX. Canaccord Genuity Group reduced their target price on TransMedics Group from $169.00 to $109.00 and set a “buy” rating for the company in a report on Tuesday, October 29th. Oppenheimer dropped their target price on shares of TransMedics Group from $200.00 to $125.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 29th. Piper Sandler restated an “overweight” rating and issued a $180.00 price target on shares of TransMedics Group in a research report on Tuesday, October 29th. Needham & Company LLC lowered their price objective on shares of TransMedics Group from $208.00 to $109.00 and set a “buy” rating on the stock in a research report on Tuesday, October 29th. Finally, JPMorgan Chase & Co. decreased their target price on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a research report on Tuesday, October 29th. One analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, TransMedics Group presently has a consensus rating of “Buy” and an average price target of $144.80.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.